RWRuonan Wang

Ruonan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ruonan Wang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Ping Wu

    Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, 030000 Taiyuan, Shanxi, China

    2 shared publications
  • Sijin Li

    Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, China

    2 shared publications
  • Bing Liu

    Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, 030000 Taiyuan, Shanxi, China

    1 shared publication
  • Hua Wei

    Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, P. R. China

    1 shared publication
  • Jun Zhang

    Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, 030000 Taiyuan, Shanxi, China

    1 shared publication
  • Junshun Chang

    Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, 030000 Taiyuan, Shanxi, China

    1 shared publication

Latest Publications

  • Open Access

    Dapagliflozin Attenuates Post-Infarction Myocardial Fibrosis Associated With the Inhibition of NLRP3-Dependent Inflammation

    by Xiao Han, Jun Zhang, Pingchang Guo, Junshun Chang, Bing Liu, Xin Diao, Ping Wu, Sheng He, Hua Wei, Wenjuan Dai, et al.

    Background: Sodium–glucose cotransporter 2 (SGLT2) inhibitors have attracted considerable attention owing to their unexpected cardioprotective benefits in addition to glycemic control. Indeed, these inhibitors have been reported to exert anti-fibrotic effects and ameliorate NACHT, leucine-rich repeat (LRR), and pyrin domain-containing protein 3 (NLRP3)-dependent inflammation. However, whether SGLT2 inhibitors (SGLT2is) attenuate post-infarction myocardial fibrosis by suppressing NLRP3-dependent signaling remains unclear. Thus, this study aimed to investigate the mechanisms through which the SGLT2is dapagliflozin (DAPA) mitigates post-infarction myocardial fibrosis, with particular emphasis on the modulation of NLRP3-dependent signaling. Methods: Male Sprague-Dawley rats were used to establish a myocardial infarction (MI) model via left coronary artery ligation and were treated with DAPA (1 mg/kg/day). Cardiac magnetic resonance imaging was performed to evaluate cardiac function and remodeling. Serial 18F-fibroblast activation protein inhibitor-74 (18F-FAPI-74) positron emission tomography (PET) was used to track temporal changes in cardiac fibroblast (CF) activation. Myocardial fibrosis and NLRP3-dependent signaling were assessed ex vivo. The effects of DAPA on NLRP3-dependent signaling, fibroblast proliferation, phenotypic transition, and collagen synthesis were determined in vitro using cardiac fibroblasts (CFs) stimulated with lipopolysaccharide. Results: Compared with untreated MI rats, MI rats treated with DAPA exhibited significantly lower left ventricular (LV) end-systolic volume, LV end-diastolic volume, and LV mass, along with improved LV ejection fraction (57.6 ± 2.4% vs. 54.4 ± 2.1% in the MI group; p = 0.011). LV fibrosis was reduced in DAPA-treated MI rats (20.1 ± 1.9% vs. 31.1 ± 4.0% in the MI group; p = 0.0026), and fibrosis markers were significantly downregulated. In vivo 18F-FAPI-74 PET revealed that DAPA suppressed CF activation, as demonstrated by significantly reduced 18F-FAPI-74 uptake in the infarcted region. In infarcted cardiac tissue, DAPA inhibited the expression of the NLRP3 inflammasome, interleukin-1 beta (IL-1β), and interleukin-18 (IL-18). CF experiments performed in vitro showed that DAPA inhibited the nuclear factor kappa B (NF-κB)/NLRP3 pathway and attenuated CF proliferation, phenotypic transition, and collagen synthesis. Conclusions: By suppressing CF activation, DAPA improved myocardial fibrosis, adverse LV remodeling, and cardiac function post-MI, in association with inhibition of the NF-κB/NLRP3 pathway. 18F-FAPI-74 PET enabled non-invasive visualization of the anti-fibrotic effects of DAPA post-MI and may serve as a tool to monitor anti-fibrotic treatment efficacy after MI.

  • Open Access

    Prognostic Value of Resting Left Ventricular Sphericity Indexes in Coronary Artery Disease With Preserved Ejection Fraction

    by Ping Wu, Yuting Zhao, Xiaoshan Guo, Xia Liu, Yingqi Hu, Yuxin Xiao, Li Xu, Nan Huang, Yuanyuan Li, Yanhui Wang, et al.

    Background: Adverse left ventricular remodeling is a significant cardiovascular predictor for patients with coronary artery disease and preserved left ventricular ejection fraction (LVEF). However, the remodeling indexes reflecting left ventricular spherization by myocardial perfusion imaging are underexplored. Methods and Results: 727 patients (mean age 59.8±13.5 years, 329 women) diagnosed or suspected coronary artery disease with preserved LVEF who underwent resting myocardial perfusion imaging were retrospectively enrolled. The myocardial perfusion imaging findings including the total perfusion deficit and sphericity indexes (shape index (SI) and eccentricity index (EI) obtained from gated (QGS) and non‐gated (QPS) images) were collected. Major adverse cardiovascular events (MACE) were followed up for 45.1±22.0 months. All patients were divided into 4 subgroups based on total perfusion deficit at 10% and LVEF at 65%. Univariable comparative analyses were performed in 5 cohorts (all patients and 4 subgroups). Patients who experienced MACE displayed higher SI and/or lower EI (all P QPS in all 5 cohorts, for EI QPS and EI QGS in 4 cohorts, and for end‐systolic and end‐diastolic SI QGS in 3 cohorts (all P QPS is particularly promising across different perfusion or preserved functional conditions.